QALYs: Are they helpful to decision makers?

PharmacoEconomics

Volumn 24, Issue 10, 2006, Pages 947-952

  McGregor, Maurice ^a,b,d   Caro, J Jaime ^b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CARO RESEARCH INSTITUTE   (United States)

^d ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATTITUDE TO HEALTH; BIOMEDICAL TECHNOLOGY ASSESSMENT; BUDGET; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; HEALTH CARE; HEALTH CARE POLICY; INFORMATION PROCESSING; LIFE EXPECTANCY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; REVIEW; THEORETICAL MODEL; VALIDITY;

COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE COSTS; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 33749355349     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624100-00002     Document Type: Review

References (37)

1. Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Ontario: Ministry of Health, 1994
2. Maynard A. Quality control in the regulation of pharmaceuticals. Pharmacoeconomics 2005; 23: 421-2
3. Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ 2002; 166: 44-7
4. Henry D. Economic analysis as an aid to subsidization decisions: the development of Australia's guidelines for pharmaceuticals. Pharmacoeconomics 1992; 1 (50): 4-67
5. Van Oostenbruggen MF, Jansen RB, Mir K, et al. Penny and pound wise: pharmacoeconomics from a government perspective. Pharmacoeconomics 2005; 23: 219-26
6. Weinstein HC, Stason WB. Foundation of cost-effectiveness analysis for health and medical practices. N Engl J Med 1997; 296: 716-21
7. Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
8. Ubel PA, Richardson J, Prades JL. Life-saving treatments and disabilities: are all QALYs created equal? Int J Technol Assess Health Care 1999; 15: 738-48
9. Tsuchiya A, Dolan P. The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Med Decis Making 2005; 25: 460-7
10. Nord E, Pinto JL, Richardson J, et al. Incorporating societal concerns for fairness in numerical valuations of health programs. Health Econ 1999; 8: 25-39
11. Ubel PA. Pricing life: why it's time for health care rationing. Cambridge (MA): The MIT Press, 2000
12. Nord E. Towards cost-value analysis in health care? Health Care Anal 1999; 7: 167-75
13. Gafni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics 2003; 21: 149-57
14. Mooney GK. QALY league tables: handle with care. Health Econ 1994; 2: 59-64
15. Drummond M, Torrance G, Mason J. Costs-effectiveness tables: more harm than good? Soc Sci Med 1993; 37: 33-40
16. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-42
17. Hoch JS. Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis. Expert Rev Pharmacoeconomics Outcomes Res 2004; 4: 89-99
18. Arnessen T, Trommald M. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy 2004; 9: 43-50
19. Bala M, Wood L, Zarkin GA, et al. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol 1998; 51: 667-76
20. Gregor JC, McDonald JWD, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997; 3: 265-76
21. Tsevat J, Dawson NV, Wu AW, et al. Health values of hospitalized patients 80 years or older. JAMA 1998; 279 (5): 371-5
22. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102
23. Revicki DA, Kaplan RM. Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Qual Life Res 1993 Dec; 2 (6): 477-87
24. O'Leary JF, Fairclough DL, Jankowski MK, et al. Comparison of time-trade-off utilities and rating scale values of cancer patients and their relatives: evidence for a possible plateau relationship. Med Decis Making 1995; 15: 132-7
25. Read JL, Quinn RJ, Berwick DM, et al. Preferences for health outcomes: comparison of assessment methods. Med Decis Making 1984; 4: 15-29
26. Stavem K. Quality of life in epilepsy: comparison of four preference measures. Epilepsy Res 1998; 29: 201-9
27. Chapman RH, Stone PW, Sandberg EA, et al. A comprehensive league table of cost-utility ratios and a sub-table of 'panel-worthy' studies. Med Decis Making 2000; 20: 451-67
28. Smith KJ, Roberts MS. The cost-effectiveness of sildenafil. Ann Intern Med 2000; 132: 933-7
29. Volk RJ, Cantor SB, Spann SJ, et al. Preferences of husbands and wives for prostate cancer screening. Arch Fam Med 1997; 6: 72-6
30. Krahn MD, Mahoney JE, Eckman MH, et al. Screening for prostate cancer: a decision analytic view. JAMA 1994; 272: 773-80
31. Fleming C, Wasson JH, Albertsen PC, et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993; 269: 2650-8
32. Groome PA, Hutchison TA, Tousignant P, et al. The repeatability of three methods for measuring prospective patients' values in the context of treatment choice for end-stage renal disease. J Clin Epidemiol 1999; 52: 849-60
33. Arnesen TM, Norheim OF. Quantifying quality of life for economic analysis: time out for trade off. J Med Humanit 2003; 29: 81-6
34. Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 2005; 115: E600-14
35. Williams AH, Cookson RA. Equity-efficiency trade-offs in health technology assessment. Int J Technol Assess Health Care 2006; 22 (1): 1-9
36. Coast J. Is economic evaluation in touch with society's health values? BMJ 2004; 329: 1233-6
37. McGregor M, Brophy JM. End-user involvement in Health Technology Assessment (HTA) development: a way to increase impact. Int J Technol Assess Health Care 2005; 21: 263-7